Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7BN5W)

Drug Name
LPN023 Drug Info
Indication
Disease Entry ICD 11 Status REF
IgA nephropathy MF8Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM7BN5W

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement factor B (CFB) TTA0P7K CFAB_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Complement factor B (CFB) DTT CFB 10.419 4.895 7.235 6.78
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease IgA nephropathy
ICD Disease Classification MF8Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement factor B (CFB) DTT CFB 1.63E-02 0.07 0.13
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03373461) Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation. U.S. National Institutes of Health.
2 Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166.